Novartis, a leading Swiss drugmaker, has made significant strides in the biopharma sector with three major deals, marking a substantial week in the industry. The company has committed a total of $472.5 million in upfront payments for these strategic acquisitions and partnerships, aiming to bolster its portfolio in autoimmune and cardiovascular treatments.

The first deal involves a $250 million payment to Calypso Biotech, a spin-out from Merck KGaA, for the acquisition of CALY-002, an anti-IL-15 monoclonal antibody. CALY-002 targets the cytokine IL-15, implicated in various autoimmune diseases. With Phase 1b trials already in progress for celiac disease and eosinophilic esophagitis, Novartis plans to explore its potential in a range of autoimmune conditions with high unmet medical needs.

In another significant move, Novartis has entered into two license and collaboration agreements with Shanghai Argo Biopharmaceutical, focusing on RNA-focused biotech for cardiovascular diseases. The transaction is valued at $185 million in upfront payments. These agreements grant Novartis an exclusive global license for a Phase I asset and an option to license programs for up to two cardiovascular targets. Additionally, Novartis secures an exclusive license for a Phase I/IIa program outside China and nearby regions. Shanghai Argo stands to gain from option and milestone payments, along with tiered royalties, potentially elevating the deal’s value to $4.1 billion, excluding royalties.

Shanghai Argo’s pipeline includes three cardiovascular assets, BW-01, BW-02, and BW-05, developed using their RADS platform, which allows for long-lasting treatments with potentially just one injection per year. Novartis, with a history of investing in RNA-based therapeutics, views these programs as complementary to its own pipeline in the cardiovascular realm.

These deals represent a strategic expansion for Novartis in the biopharma industry, especially following its recent investments like the 2023 acquisition of DTx Pharma for RNA-based neuroscience therapies and The Medicines Company for RNA drug inclisiran for high cholesterol, which resulted in the FDA-approved Leqvio.

Source:
https://www.fiercebiotech.com/biotech/novartis-dances-jpm-250m-calypso-buyout-185-million-rnai-alliance

Related News

Plasmid CDMO Services

We provide high quality plasmids that are ideal for any phase of the drug development cycle.

READ MORE

AAV cGMP Manufacturing

Ranging from pilot to industrial-scale AAV packaging for both in vitro and in vivo studies.

READ MORE

aav icon

AAV Capsid Engineering

Proven technology paving your path to effective therapies for cancer or genetic disorder

READ MORE